Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer
- Status
- UNKNOWN
- Phase
- PHASE4
Clinical Trials Related to Cetuximab
Related studies linked through entity extraction aliases.
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
- Status
- TERMINATED
- Phase
- PHASE1
MLN8237 in Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
- Status
- COMPLETED
- Phase
- PHASE2
Colorectal Cancer (CRC) Cetuximab Elderly Frail
- Status
- TERMINATED
- Phase
- PHASE2
Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin
- Status
- COMPLETED
- Phase
- PHASE1
Treatment Selection According to Skin Reaction to Cetuximab
- Status
- UNKNOWN
- Phase
- PHASE2
Study of ABT-700 in Subjects With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Biomarkers in Patients With Head and Neck Cancer
- Status
- COMPLETED
- Phase
- N/A
Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397
- Status
- COMPLETED
- Phase
- N/A
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
- Status
- COMPLETED
- Phase
- PHASE1
Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype
- Status
- COMPLETED
- Phase
- PHASE2
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab
- Status
- COMPLETED
- Phase
- PHASE2
Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Status
- COMPLETED
- Phase
- PHASE2
A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab
- Status
- COMPLETED
- Phase
- PHASE2